Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06345183 · ClinicalTrials.gov registry record
Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients
A clinical trial of Advanced Renal Cell Carcinoma (aRCC), sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 327
- Enrollment target
- 1
- Study location
NCT06345183 is a study of Advanced Renal Cell Carcinoma (aRCC) that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 327 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06345183, a study of Advanced Renal Cell Carcinoma (aRCC), has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 327 participants
- Enrollment target
- 1
- Study location
Study Summary
This observational study aims to describe demographic, clinical characteristics, treatment patterns outcomes of participants with advanced Renal Cell Carcinoma (aRCC) receiving either Nivolumab + Ipilimumab, or Pembrolizumab + Lenvatinib combination therapy
Conditions Studied
Interventions
- COMBINATION_PRODUCT Nivolumab + Ipilimumab combination therapy
- COMBINATION_PRODUCT Pembrolizumab + Lenvatinib combination therapy
Study Locations (1)
Ohio
- Cardinal Health - Dublin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 327 participants |
| Start Date | 2024-02-19 |
| Est. Completion | 2024-04-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06345183
The ClinicalTrials.gov registry entry for NCT06345183 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 327 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Renal Cell Carcinoma (aRCC) appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab + Ipilimumab combination therapy is the first listed.
NCT06345183 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT06345183 about?
NCT06345183 is a clinical study titled "Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients". This observational study aims to describe demographic, clinical characteristics, treatment patterns outcomes of participants with advanced Renal Cell Carcinoma (aRCC) receiving either Nivolumab + Ipilimumab, or Pembrolizumab + Lenvatinib combination therapy
What is the current status of trial NCT06345183?
This trial is currently completed. The enrollment target is 327 participants. The study started on 2024-02-19. Estimated completion is 2024-04-04.
What conditions does trial NCT06345183 study?
This clinical trial studies the following conditions: Advanced Renal Cell Carcinoma (aRCC).
What interventions are being tested in trial NCT06345183?
The interventions under investigation include: Nivolumab + Ipilimumab combination therapy (COMBINATION_PRODUCT), Pembrolizumab + Lenvatinib combination therapy (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06345183?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06345183 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Renal Cell Carcinoma (aRCC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.